Trump Takes Aim At Drug Companies, Again
Insights - In case you haven’t already seen the quotes, Donald Trump took aim at the pharmaceutical industry in a press conference this afternoon, sending bio/pharma stocks … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Why Sarepta’s Latest May Start a Sentiment Shift
Research - Sarepta Therapeutics (SRPT) is presenting at the JPMorgan Healthcare Conference right now, and released the first figures from the launch of Exondys 51. 250 patients … Continue Reading
Premium
Get Ready for JPM: New Year Updates
Research - Revance Therapeutics (RVNC) just doesn’t stop. After hours on Thursday the company issued a 2017 update. Though we note nothing critical here, the company now … Continue Reading
Premium
Merry Christmas! Watch Our December Webinar
Research - A recording of last night’s webinar is available for your leisurely viewing this holiday weekend. Last night Mr. King focused primarily on January and early … Continue Reading
Premium
Healthcare Lags: What To Look For Next
Insights - U.S. equities continue to sit at all-time highs, with financials, transportation, and energy leading the way, while biotech lags. The under-performance isn’t just from biotech/drug … Continue Reading
Read now
Revance’s Latest: Incremental Positive, More To Come
Insights - Revance Therapeutics’ (RVNC) cervical dystonia results were released after the bell on Monday. The phase 2 trial was an open-label dose-ranging study to evaluate the … Continue Reading
Premium
Little Trump Comment Takes Down Biotech Stocks
Insights - Biotech stocks are getting shellacked today due to a Trump comment in Time’s “Person of the Year” edition. It’s quite literally a single comment on … Continue Reading
Read now